At a glance
- Originator University of Sydney
- Developer Collaborative Medicinal Development
- Class Antineoplastics; Cyclohexanes; Pyridines; Small molecules; Thiosemicarbazones
- Mechanism of Action Cell death stimulants; Gene expression stimulants; Iron chelating agents; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO, Capsule)
- 27 Sep 2016 Chemical structure information added
- 27 Sep 2016 Preclinical data in Cancer released by Collaborative Medicinal Development (Collaborative Medicinal Development website, September 2016)